Outlook Therapeutics stock costs EUR 0.44, volume 59.0 percent below average

Published on 10/15/2026 at 22:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Trading volume reached 5,318,221 shares on October 15, 2026. Outlook Therapeutics stock cost EUR 0.44 at 10:52 p.m. CEST.

Market position in three figures

Trading volume reached 5,318,221 shares on October 15, 2026.
Outlook Therapeutics stock cost EUR 0.44 at Lang & Schwarz on October 15, 2026 at 10:52 p.m. CEST.
The company had a USD 121.7 million market capitalization and a USD 0.16 to USD 2.54 52-week range.

OTLK, US69012T3059, Illustration mit AI erstellt.

Outlook Therapeutics stock traded at EUR 0.44 at Lang & Schwarz on October 15, 2026 at 10:52 p.m. CEST, while volume reached 5,318,221 shares. The quote gives investors a euro view of a Nasdaq-listed biotechnology company whose valuation remains tied to the launch path for LYTENAVA.

Outlook Therapeutics' investor-relations page describes LYTENAVA as an ophthalmic formulation of bevacizumab for wet age-related macular degeneration and identifies the United States, European Union and United Kingdom as target markets. The company also describes commercial support from Cencora for logistics, distribution and pharmacovigilance services, according to Outlook Therapeutics.

Volume trails its average

The October 15 volume was 5,318,221 shares against an average of 12,963,359 shares, putting activity 59.0 percent below the average. That comparison is more informative than the raw count because it places the session in the stock's recent trading pattern.

On Nasdaq, Outlook Therapeutics last traded at USD 0.50 on October 15, 2026 at 4:00 p.m. ET. The home-market quote ranged from USD 0.44 to USD 0.51 during the session, a spread of USD 0.07.

The euro quote follows Nasdaq

The 52-week range on Nasdaq was USD 0.16 to USD 2.54 as of October 15, 2026. The company's USD 121.7 million market capitalization places the current equity value well below the upper end of that range, while the negative trailing P/E of minus 0.27 reflects losses rather than a positive earnings multiple.

Valuation and operating profile

Outlook Therapeutics is a biotechnology company focused on ophthalmic medicines. Its investor-relations materials identify LYTENAVA as the central commercial product and state that the product is authorized in the European Union and the United Kingdom as well as approved in the United States.

The company named Greg DiPasquale chief commercial officer on October 9, 2026, according to its investor-relations page. The appointment came after an October 6, 2026 investor presentation about the company's commercial planning, but that announcement is not the basis of this market report.

Market position and next steps

Nasdaq-listed Outlook Therapeutics had a USD 121.7 million market capitalization and traded at USD 0.50 on October 15, 2026 at 4:00 p.m. ET. The business profile and the product timeline remain the main company-specific reference points for assessing the stock's market position.

Euro quote after hours

The euro quote stood at EUR 0.44 at Lang & Schwarz on October 15, 2026 at 10:52 p.m. CEST. The Xetra comparison is omitted here because the dated closing value could not be established from the eligible venue records.

The further course of trading is shown by the continuously updated real-time quote of Outlook Therapeutics stock.